Quality of life in patients with psoriasis

被引:238
作者
Bhosle, Monali J.
Kulkarni, Amit
Feldman, Steven R.
Balkrishnan, Rajesh
机构
[1] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA
[2] Ohio State Univ, Sch Publ Hlth, Columbus, OH 43210 USA
[3] Wake Forest Univ, Bowman Gray Sch Med, Dept Dermatol, Ctr Dermatol Res, Winston Salem, NC 27157 USA
关键词
D O I
10.1186/1477-7525-4-35
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Psoriasis is one of the prevalent skin conditions in the United States. This chronic condition has a significant negative impact on patients' quality of life. Psoriasis has been linked to the depression and suicidal tendencies in the patients. The costs associated with decrements in quality of life, lost productivity, and work absenteeism may be enormous, increasing overall costs associated with the disease management. This review attempts to outline different quality of life measures available for psoriasis and describes their use in studies examining patient reported outcomes associated with pharmacological interventions for psoriasis. Factors associated with quality of life in psoriasis patients are described. It further describes physician's role in the psoriasis management to improve patients' overall well-being.
引用
收藏
页数:7
相关论文
共 49 条
  • [1] Quality of life issues in psoriasis
    Choi, J
    Koo, JYM
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 49 (02) : S57 - S61
  • [2] The impact of psoriasis on quality of life
    De Arruda, LHF
    De Moraes, APF
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2001, 144 : 33 - 36
  • [3] The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients
    Devrimci-Ozguven, H
    Kundakci, N
    Kumbasar, H
    Boyvat, A
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2000, 14 (04) : 267 - 271
  • [4] An Italian study on psoriasis and depression
    Esposito, M
    Saraceno, R
    Giunta, A
    Maccarone, M
    Chimenti, S
    [J]. DERMATOLOGY, 2006, 212 (02) : 123 - 127
  • [5] Decision points for the initiation of systemic treatment for psoriasis
    Feldman, SR
    Koo, JYM
    Menter, A
    Bagel, J
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 53 (01) : 101 - 107
  • [6] The economic impact of psoriasis increases with psoriasis severity
    Feldman, SR
    Fleischer, AB
    Reboussin, DM
    Rapp, SR
    Bradham, DD
    Exum, ML
    Clark, AR
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 37 (04) : 564 - 569
  • [7] Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial
    Feldman, SR
    Gordon, KB
    Bala, M
    Evans, R
    Li, S
    Dooley, LT
    Guzzo, C
    Patel, K
    Menter, A
    Gottlieb, AB
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2005, 152 (05) : 954 - 960
  • [8] Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost
    Feldman, SR
    Garton, R
    Averett, W
    Balkrishnan, R
    Vallee, J
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (09) : 1525 - 1533
  • [9] FINLAY AY, 1995, BRIT J DERMATOL, V132, P236
  • [10] Psychologic factors in psoriasis: Consequences, mechanisms, and interventions
    Fortune, DG
    Richards, HL
    Griffiths, CEM
    [J]. DERMATOLOGIC CLINICS, 2005, 23 (04) : 681 - +